INZY
Price
$2.75
Change
-$0.19 (-6.46%)
Updated
Dec 18, 04:19 PM (EDT)
92 days until earnings call
RNA
Price
$31.26
Change
-$1.48 (-4.52%)
Updated
Dec 18, 04:30 PM (EDT)
76 days until earnings call
Ad is loading...

INZY vs RNA

Header iconINZY vs RNA Comparison
Open Charts INZY vs RNABanner chart's image
Inozyme Pharma
Price$2.75
Change-$0.19 (-6.46%)
Volume$400
CapitalizationN/A
Avidity Biosciences
Price$31.26
Change-$1.48 (-4.52%)
Volume$1.46K
CapitalizationN/A
INZY vs RNA Comparison Chart
Loading...
INZY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INZY vs. RNA commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INZY is a Hold and RNA is a Hold.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (INZY: $2.94 vs. RNA: $32.74)
Brand notoriety: INZY and RNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INZY: 94% vs. RNA: 114%
Market capitalization -- INZY: $188.87M vs. RNA: $3.91B
INZY [@Biotechnology] is valued at $188.87M. RNA’s [@Biotechnology] market capitalization is $3.91B. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INZY’s FA Score shows that 1 FA rating(s) are green whileRNA’s FA Score has 0 green FA rating(s).

  • INZY’s FA Score: 1 green, 4 red.
  • RNA’s FA Score: 0 green, 5 red.
According to our system of comparison, both INZY and RNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INZY’s TA Score shows that 4 TA indicator(s) are bullish while RNA’s TA Score has 4 bullish TA indicator(s).

  • INZY’s TA Score: 4 bullish, 4 bearish.
  • RNA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, INZY is a better buy in the short-term than RNA.

Price Growth

INZY (@Biotechnology) experienced а -1.34% price change this week, while RNA (@Biotechnology) price change was -9.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.65%. For the same industry, the average monthly price growth was +1.45%, and the average quarterly price growth was +4.23%.

Reported Earning Dates

INZY is expected to report earnings on Mar 20, 2025.

RNA is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-3.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNA($3.91B) has a higher market cap than INZY($189M). RNA YTD gains are higher at: 261.768 vs. INZY (-30.986). INZY has higher annual earnings (EBITDA): -90.3M vs. RNA (-322.04M). RNA has more cash in the bank: 1.59B vs. INZY (132M). RNA has less debt than INZY: RNA (7.6M) vs INZY (46.8M). RNA has higher revenues than INZY: RNA (10.1M) vs INZY (0).
INZYRNAINZY / RNA
Capitalization189M3.91B5%
EBITDA-90.3M-322.04M28%
Gain YTD-30.986261.768-12%
P/E RatioN/AN/A-
Revenue010.1M-
Total Cash132M1.59B8%
Total Debt46.8M7.6M616%
TECHNICAL ANALYSIS
Technical Analysis
INZYRNA
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 6 days ago
86%
Bullish Trend 24 days ago
87%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 6 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
INZY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SRFMX17.18-0.05
-0.29%
Sarofim Equity
INGIX21.08-0.08
-0.38%
Voya US Stock Index Port I
FXAIX210.71-0.82
-0.39%
Fidelity 500 Index
VYRIX12.01-0.09
-0.74%
VY® T. Rowe Price Divers Mid Cap Gr R6
CFIPX25.04-0.86
-3.32%
Franklin Global Equity A

INZY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INZY has been loosely correlated with BEAM. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if INZY jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INZY
1D Price
Change %
INZY100%
-2.65%
BEAM - INZY
57%
Loosely correlated
-1.21%
NAUT - INZY
53%
Loosely correlated
-1.00%
ABOS - INZY
49%
Loosely correlated
-0.51%
DNLI - INZY
49%
Loosely correlated
-0.30%
RXRX - INZY
48%
Loosely correlated
-4.30%
More

RNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNA has been loosely correlated with DYN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNA
1D Price
Change %
RNA100%
-1.95%
DYN - RNA
48%
Loosely correlated
+0.23%
ACLX - RNA
41%
Loosely correlated
-1.67%
VCYT - RNA
40%
Loosely correlated
-2.52%
INZY - RNA
39%
Loosely correlated
-2.65%
RVMD - RNA
39%
Loosely correlated
+1.01%
More